The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
March 30th 2025
Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.
The Utilization of SGLT2 Inhibitors in the Treatment of Cardiovascular Disease, Diabetes, and Chronic Kidney D...
1.5 Credits / Cardiology; Endocrinology, Diabetes & Metabolism; Nephrology
View More
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
Updated Guidelines in the Management of Atrial Fibrillation and Application for Pharmacists
1.5 Credits / Cardiology
View More
The Expanding Role of Nonstatin Therapies in Reducing LDL-Cholesterol Levels to Prevent and Manage ASCVD: A Re...
1.5 Credits / Cardiology
View More
Elevating Cardiac Care: Insights From Pharmacists Across Practice Settings
1.0 Credit / Cardiology
View More
The Evolving Treatment Paradigm for the Management of Pulmonary Arterial Hypertension: Strategies to Optimize ...
1.5 Credits / Cardiology
View More
Optimizing Care for Chronic Worsening Heart Failure: The Key Role of Pharmacists in Integrating Therapies
1.5 Credits / Cardiology
View More
Lipoprotein(a) and Beyond: Emerging Paradigms in Atherosclerotic Cardiovascular Disease Prevention
1.5 Credits / Cardiology
View More
Therapies in Lowering LDL-Cholesterol Levels for the Primary and Secondary Prevention of Atherosclerotic Cardi...
0.75 Credit / Cardiology
View More
Recent Developments in the Management of Heart Failure With Preserved Ejection Fraction
1.0 Credit / Cardiology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Harnessing the Potential of SGLT2 Inhibitors in Cardiorenal Metabolic Health: Strategies for Long-term Care an...
1.0 Credit / Cardiology, Endocrinology, Diabetes, & Metabolism, Nephrology
View More
Mastering Hypertrophic Cardiomyopathy: Cutting-Edge Therapies for Better Outcomes
1.5 Credits / Cardiology
View More
Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy
1.0 Credit / Cardiology
View More
Exploring Advances in the Management of DOAC-Associated Bleeding With Reversal Agents: Role of the Health-Syst...
1.5 Credits / Cardiology, Patient Safety
View More
First Antibody Therapy for Acute Myocardial Infarction Granted FDA Fast Track Designation
March 25th 2025If approved, this novel monoclonal antibody therapy could become a standard of care emergency option for patients with acute myocardial infarction, which affects millions in the United States and across the world.
Read More
FDA Approves Vutrisiran to Reduce Cardiovascular Death, Hospitalizations in Patients With ATTR-CM
Published: March 21st 2025 | Updated: March 21st 2025Vutrisiran becomes the first and only therapeutic FDA-approved to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.
Read More
FDA Approves SCN-102, Liquid Oral Suspension Formulation of Losartan
March 18th 2025The treatment is indicated for patients aged 6 and older with hypertension, the reduction of stroke in hypertension and left ventricular hypertrophy, and diabetic nephropathy in certain patients with type 2 diabetes.
Read More
Pharmacists Will Play an Essential Role in Optimizing Vutrisiran Therapy for ATTR-CM
Published: March 10th 2025 | Updated: March 21st 2025If approved, vutrisiran would be the first FDA-approved therapy to treat both the polyneuropathy and cardiomyopathy aspects of transthyretin amyloidosis (ATTR).
Read More
Paradoxical Hypotension After Inadvertent Intravenous Administration of Epinephrine
Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.
Read More